Rationale Stimuli that are paired with opioid withdrawal can themselves produce effects similar to withdrawal that might promote relapse. Objective This study compared precipitated and conditioned withdrawal and tested whether withdrawal is modified by clonidine or morphine. Methods Morphine-treated rats (10 mg/kg/12 h) received naloxone (3.2 mg/kg) in a novel environment (conditioned stimuli [CS]). Other rats received naloxone in the absence of the CS. Body weight and observable signs were used to measure withdrawal. Results Naloxone produced weight loss and withdrawal signs in morphine-treated rats. Following pairings of the CS and naloxone, the CS alone had effects similar to naloxone; conditioned withdrawal was greater after three naloxone/CS pairings, as compared to one, and with longer morphine treatment. Antagonist-precipitated withdrawal was greater in rats that previously were physically dependent on morphine, as compared to withdrawal in rats that were never dependent; however, conditioned withdrawal did not differ between groups. When administered concurrently with naloxone, clonidine (0.1 mg/kg) attenuated some precipitated withdrawal signs, although conditioned withdrawal was largely unchanged. Administration of 10 mg/kg of morphine before the CS alone attenuated all conditioned withdrawal signs, whereas 0.1 mg/kg of clonidine before the CS alone reduced some directly observable signs and not weight loss. Conclusions Conditioned withdrawal occurs rapidly and is greater with longer periods of morphine treatment or more pairings of naloxone and the CS; however, a history of physical dependence does not increase conditioned withdrawal. Modification of conditioned withdrawal by drugs might be a useful approach for treating relapse.
precipitated or spontaneous withdrawal, the stimulus presented alone can elicit withdrawal signs (Irwin and Seevers 1956; Goldberg and Schuster 1967; Wikler and Pescor 1967; O'Brien et al 1976) . For example, morphinedependent rats exhibit wet-dog shakes when placed in an environment where they previously experienced spontaneous withdrawal (Wikler and Pescor 1967) . After lights or tones are paired with an opioid antagonist in morphinetreated rats, presentation of those stimuli alone disrupts food-maintained responding and produces ptosis and diarrhea-signs of withdrawal (Schnur 1992; McNally and Akil 2001; Amitai et al. 2006) . Conditioned withdrawal can persist for long periods. Conditioned effects are evident in monkeys for up to 4 months after morphine discontinuation (Goldberg and Schuster 1967) and formerly opioiddependent individuals report withdrawal-like symptoms months after the last drug administration (McLellan et al. 1986 ). Because these conditioned effects last longer than the withdrawal syndrome itself, they might contribute to relapse long after drug use is terminated.
In the current study, withdrawal was precipitated by naloxone in morphine-treated rats and changes in body weight and directly observable withdrawal signs were assessed; naloxone was paired with peppermint odor and a novel, wire-mesh floor, and when these conditioned stimuli (CS) were later presented alone, effects similar to those produced by naloxone were observed. Withdrawal can be conditioned to the discontinuation of treatment (Parker et al. 1973) ; however, the current study used antagonist-precipitated withdrawal for conditioning because more robust withdrawal signs were observed following naloxone administration than following discontinuation of treatment and because acute withdrawal occurs more reliably when it is precipitated by an antagonist. Thus, withdrawal that is conditioned by acute or repeated intermittent injections of morphine can be compared to withdrawal that is conditioned by chronic, daily morphine treatment.
The current study extends previous results (Goldberg and Schuster 1967; Azar et al. 2003; Amitai et al. 2006 ) on conditioned withdrawal by assessing changes in body weight and directly observable withdrawal signs; many previous studies examined other withdrawal signs, including suppression of operant responding or place aversion conditioning (Goldberg and Schuster 1967; Azar et al. 2003; Amitai et al. 2006) . The current study also increases the number of treatment conditions examined because larger doses of morphine and naloxone are generally required to elicit weight loss and directly observable withdrawal signs (Schulteis et al. 1998) . Finally, this study tested for extinction of conditioned withdrawal. Although conditioned withdrawal can persist for many weeks (Stinus et al. 2000) , the effects wane when the CS is presented repeatedly in the absence of the unconditioned stimulus. One possibility is that withdrawal signs are differentially resistant to extinction; the current study examined whether the time course of conditioned withdrawal is similar for different signs.
Initially, the effect of varying the number of conditioning trials or the duration of morphine treatment on conditioned withdrawal was studied. Although conditioned withdrawal can be observed after one pairing of naloxone and the CS (Azar et al. 2003) , the magnitude of conditioned withdrawal can increase as the number of pairings or the duration of morphine treatment increases. The current study examined precipitated and conditioned withdrawal in separate groups that received morphine before either one or each of three conditioning trials in which naloxone was paired with the CS; three trials have been shown to produce robust and persistent conditioned withdrawal (Stinus et al. 2000) . Differences between repeated intermittent morphine treatment, in which rats received morphine only before each of three conditioning trials which were separated by 2 days, and chronic, daily morphine treatment on conditioned withdrawal were also evaluated.
This study also assessed whether precipitated or conditioned withdrawal is greater in rats that were previously dependent on morphine. Repeated experience with precipitated withdrawal in opioid-treated subjects can enhance sensitivity to withdrawal ) which might increase conditioned withdrawal. Thus, rats received morphine chronically using treatment conditions that were shown to produce dependence, and conditioning trials began 8 days after discontinuation of treatment (i.e., after spontaneous withdrawal had dissipated); results were compared to those from rats that never received morphine chronically.
A final study examined pharmacological modification of precipitated and conditioned withdrawal. The α2 adrenergic agonist clonidine reduces some withdrawal signs (Sparber and Meyer 1978; Kleber et al. 1980; Rosen et al. 1996; Holtzman 1985) . In morphine-treated rats, clonidine attenuates naloxone-precipitated disruptions in operant responding and conditioned place aversion, and it can prevent the development of conditioned withdrawal (Schulteis et al. 1998 ). In the current study, precipitated and conditioned withdrawal was examined in rats that received clonidine with naloxone during conditioning trials. One strategy for reducing the impact of conditioned withdrawal on relapse might be to suppress withdrawal signs that emerge when conditioned stimuli are encountered. The ability to alter the expression of conditioned withdrawal was examined by administering either morphine or clonidine before tests for conditioned withdrawal. Apparatus During sessions, rats were placed into clear, polycarbonate chambers similar in appearance to the home cage. Absorbent pads were placed in the bottom of each chamber, and a wire-mesh floor was placed on top of the absorbent pad. Three drops of commercially available peppermint oil (Sun Harvest Farms, San Antonio, TX, USA) were placed on the absorbent pad. The wire-mesh floor and peppermint oil served as the CS.
Methods

Subjects
Procedure These studies comprise five experiments conducted in nine separate groups of rats as outlined in Table 1 . Each group received morphine, although the duration of morphine treatment varied among groups. Preliminary studies showed that doses of morphine larger than 10 mg/kg produced untoward effects, although naloxone did not produce robust withdrawal in rats that received a single injection of 10 mg/kg of morphine. Consequently, Groups 1, 3, and 6 received two injections of 10 mg/kg of morphine 14 h apart on three separate occasions; Group 2 received only two injections of 10 mg/kg of morphine 14 h apart on one occasion (i.e., repeated intermittent). Other groups of rats received morphine twice daily for 14 (Group 6) or 21 (Groups 4, 5, 7, 8, and 9) days. Prior to repeated intermittent administration of morphine for conditioning, Group 6 received 10 mg/kg/12 h of morphine for 14 days. A 14-day period of morphine treatment was chosen because, under these conditions, withdrawal emerged after discontinuation of morphine treatment (McNally and Akil 2001; Kalinichev and Holtzman 2003) . Groups 4, 5, 7, 8 , and 9 received 10 mg/kg/12 h of morphine for 21 days; conditioning trials began on day 15 of morphine treatment with sessions conducted 2 h after morphine administration. The last conditioning trial occurred on day 21 and treatment was discontinued the next day.
During conditioning trials, rats received 3.2 mg/kg of naloxone and were immediately placed in the cage with the CS for 30 min. Body weights were taken immediately before and 30 min after administration of naloxone. Although 16 withdrawal signs were recorded, only four signs (ptosis; leaning, in which rats used the walls of the cage for support; freezing; and salivation) occurred reliably and are reported here. Observations were conducted by persons blinded to treatments and began 5 min after naloxone administration. Preliminary studies showed that withdrawal signs emerged 5-10 min after naloxone. Signs were recorded as present or absent every 30 s for a 5-min period (maximum frequency score=10 for each sign). In preliminary studies, 3.2 mg/kg of naloxone produced robust withdrawal signs and had a rapid onset (5 min) and short duration of action, factors which might increase the salience of withdrawal during a Repeated intermittent treatment: 10 mg/kg of morphine given 16 and 2 h before each conditioning trial. Chronic treatment: 10 mg/kg/12 h of morphine b Unpaired: saline given before conditioning trials; 3.2 mg/kg of naloxone given on different days. Paired: 3.2 mg/kg of naloxone given before conditioning trials; saline given on different days c Days after the last conditioning trial when tests for conditioned withdrawal were conducted conditioning. With the exception of Group 2 which received only one conditioning trial, rats received three conditioning trials, regardless of morphine treatment. When three conditioning trials were used, they were separated by 2 days during which rats received saline in the absence of the CS. Two control groups (unpaired; Groups 1 and 4; Table 1 ) received morphine and naloxone on three separate occasions, as described above, although they remained in the home cage after receiving drug; on three different days, those rats received saline before being placed in the cage with the CS. Body weight was obtained daily, and withdrawal signs were measured only on conditioning days. To examine extinction, conditioned withdrawal was examined repeatedly after the last conditioning trial. Rats were placed in the cage with the CS after receiving saline. For groups that received repeated intermittent morphine treatment, tests occurred 1, 8, 15, and 22 days after the last conditioning trial (Groups 1-3 and 6). For groups that received morphine chronically, tests occurred 8, 15, and 22 days after treatment (Groups 4, 5, 7, 8, and 9); tests were not conducted for the first 7 days after discontinuation of chronic morphine treatment to avoid discontinuation-induced withdrawal, which was monitored by measuring body weight and directly observable signs twice daily for 7 days.
Experiment 1: Compare conditioned withdrawal following one or three conditioning trials in rats receiving repeated intermittent morphine. Six rats received 10 mg/kg of morphine 16 and 2 h before one (Group 2) or each of three (Group 3) conditioning trials (Table 1) . A separate group of six rats received the same three pairings of morphine and naloxone, but those pairings did not occur in the presence of the CS (Group 1); morphine was administered every 3rd day, and drug was not administered during the two intervening days.
Experiment 2: Compare conditioned withdrawal in rats receiving repeated intermittent or chronic morphine. To determine whether chronic treatment produces more robust conditioned withdrawal than repeated intermittent treatment, two groups of six rats received 10 mg/kg/12 h of morphine for a total of 21 days with the first of three conditioning trials conducted on day 15. During conditioning trials (days 15, 18, and 21), naloxone was paired with the CS in Group 5 (Table 1) and not paired with the CS in Group 4. Morphine was discontinued on the day after the last conditioning trial; tests for conditioned withdrawal occurred 8, 15, and 22 days later. Conditioned withdrawal in rats treated chronically with morphine (Group 5) was compared to conditioned withdrawal in rats that received repeated intermittent morphine (Group 3).
Experiment 3: Determine whether a history of physical dependence alters conditioned withdrawal. Six rats received 10 mg/kg/12 h of morphine for 14 days (Group 6; Table 1 ). Conditioning trials began 8 days after termination of treatment when withdrawal signs were no longer evident. The three conditioning trials were identical to those described above after repeated intermittent morphine. Precipitated and conditioned withdrawal in Group 6 was compared to withdrawal in rats that were never physically dependent (Group 3).
Experiment 4: Determine whether clonidine affects the development of conditioned withdrawal. Six rats received morphine chronically for 21 days; during conditioning trials, 0.1 mg/kg of clonidine was administered 10 min before conditioning with naloxone and the CS (Group 7; Table 1 ). This dose of clonidine attenuated antagonistprecipitated diarrhea and weight loss in morphinedependent rats (Sparber and Meyer 1978; DiStefano and Brown 1985; Holtzman 1985) . Precipitated and conditioned withdrawal was compared to withdrawal in rats that did not receive clonidine prior to naloxone (Group 5).
Experiment 5: Determine whether morphine or clonidine modifies the expression of conditioned withdrawal. Two separate groups of six rats received morphine chronically for 21 days and three conditioning trials. Eight days after discontinuation of treatment, rats in Group 8 (Table 1) received 10 mg/kg of morphine 5 min before the test for conditioned withdrawal and those in Group 9 received 0.1 mg/kg of clonidine 10 min before the test. Saline was administered before tests for conditioned withdrawal conducted on days 15 and 22. Conditioned withdrawal was compared to withdrawal in rats that received saline on test days (Group 5). Data analyses Precipitated withdrawal signs were analyzed using one-factor analysis of variance (ANOVA) when more than two treatment groups were compared or t test when two groups were compared; a post hoc Student-Newman-Keuls test was used to further evaluate differences among means (GraphPad Prism version 5.01 for Windows; GraphPad Software, San Diego, CA, USA). Conditioned withdrawal signs were analyzed using two-factor repeated measures ANOVA with groups as the between-subjects factor and test day as the within-subjects factor, followed by Bonferroni post hoc tests. Signs observed during the first test for conditioned withdrawal were compared with those observed during precipitated withdrawal using a paired t test. Data were considered significantly different when p<0.05.
Drugs
Results
Experiment 1: Compare conditioned withdrawal following one or three conditioning trials in rats receiving repeated intermittent morphine. Naloxone precipitated withdrawal in rats that received morphine on one or three occasions (Groups 2 and 3, points above PW, left panels, Fig. 1 ). Withdrawal signs were not evident when rats received saline before they were placed in the cage with the CS (Group 1, Fig. 1 ). Naloxone significantly decreased body weight and increased ptosis, leaning and freezing but not salivation (F[2,15]≥4.19, p≤0.036; F[2,15]=3.07, NS, respectively). Body weight, ptosis, and leaning were not significantly different between Groups 2 and 3.
Conditioned withdrawal was evident during the first test which occurred the day after the last conditioning trial, although some conditioned withdrawal signs were not as robust as those precipitated by naloxone (compare points above 1 and PW, left panels, Fig. 1 . During the first test for conditioned withdrawal, body weight, ptosis, leaning, and freezing were significantly different in rats that received three conditioning trials (Group 3), as compared to rats that received one conditioning trial (Group 2; left panels, Fig. 1 ). These conditioned effects decreased over time, although weight loss and freezing were still evident during the second test for conditioned withdrawal.
Experiment 2: Compare conditioned withdrawal in rats receiving repeated intermittent or chronic morphine. Dependence developed after 14 days of treatment with 10 mg/ kg/12 h of morphine, as evidenced by the emergence of withdrawal following discontinuation of treatment (data not shown). Body weights were decreased for 1 to 2 days and recovered by the fourth day. Directly observable withdrawal signs, including ptosis and leaning, were increased 1 day after discontinuation of morphine and recovered within 6 days. Thus, at the time when tests for conditioned withdrawal occurred (i.e., 8 days after discontinuation of morphine), withdrawal signs from the discontinuation of treatment were no longer present.
During chronic morphine treatment, 3.2 mg/kg of naloxone precipitated withdrawal, as evidenced by changes in body weight and directly observable withdrawal signs (t[10]≥ 2.57, p<0.05; points above PW, right panels, Fig. 1 ). Weight loss, freezing, and salivation were significantly different in rats receiving morphine chronically, as compared to rats that received repeated intermittent morphine (t[10]≥2.94, p≤0.015; Groups 3 and 5, Fig. 1 Weight loss, ptosis, freezing, and salivation were greater in tests for conditioned withdrawal when naloxone was paired with the CS, as compared to the signs observed when the CS was not paired with naloxone (Groups 4 and 5, Fig. 1 ) and leaning was not different in these two groups. Conditioned withdrawal signs were not significantly different between rats treated chronically or those treated less frequently with morphine (t[10]≤2.14, NS; Groups 3 and 5). When tested 15 days after the last conditioning trial, withdrawal signs were not significantly different between groups in which naloxone was paired with the CS and groups in which it was not. Experiment 3: Determine whether a history of physical dependence alters conditioned withdrawal. Naloxoneprecipitated withdrawal was significantly greater in rats with a history of physical dependence (Group 6) as compared with rats that were never dependent (Group 3). Significant differences were detected for weight loss, ptosis, freezing, and salivation (F[2,15]≥15.79, p≤0.0002) and not for leaning (F[2,15] =3.62, p=0.052; points above PW, Fig. 2 ). Post hoc tests revealed that weight loss, freezing, and salivation occurred more frequently in rats that were previously dependent, as compared with rats that were never dependent. Although a history of physical dependence appeared to enhance precipitated withdrawal, it did not impact conditioned withdrawal (Fig. 2) . A group × time interaction was detected for body weight (F[6,45]=7.11, p≤0.0001), with a main effect of time for ptosis, leaning, and freezing (F[3,45] ≥4.03, p<0.05). No significant differences were detected for salivation (F[3,45] ≤1.20, NS). One day after the last conditioning trial, weight loss, ptosis, leaning, and freezing were observed in rats that received naloxone during conditioning trials, regardless of whether they had previously been physically dependent (Groups 3 and 6, Fig. 2) , and conditioned withdrawal signs were not significantly different in the two groups. During the second test for conditioned withdrawal, which occurred 8 days after the last conditioning trial, rats that never received morphine chronically lost significantly more weight than rats that had a history of physical dependence; there was no other difference between the two groups.
Experiment 4: Determine whether clonidine affects the development of conditioned withdrawal. When 0.1 mg/kg of clonidine was administered in combination with nalox- Fig. 2 Effects of prior morphine treatment and physical dependence on precipitated and conditioned withdrawal. Data from Groups 1 and 3 are replotted on this figure. Ordinates: top panels, change in body weight (g) that occurred during the 30 min session; bottom four rows, frequency of directly observable signs. *P< 0.05 for no prior dependence versus prior dependence (Groups 3 versus 6). See Fig. 1 for other details one before the first conditioning trial, fewer withdrawal signs were observed, as compared with the signs observed when naloxone was administered alone (data not shown); some signs emerged by the third conditioning trial, although other signs did not (diamonds above PW, Fig. 3 ). Significant overall differences were observed across all dependent variables (F[2,15]≥3.72, p≤0.049). Post hoc tests revealed differences in body weight and freezing among Groups 4, 5, and 7, whereas ptosis and salivation in rats receiving naloxone in combination with clonidine were significantly different from those signs in rats receiving naloxone alone and not from those signs in rats in which naloxone was not paired with the CS. There was no difference in leaning in Groups 5 and 7.
Administration of clonidine in combination with naloxone during conditioning affected only some conditioned withdrawal signs (Fig. 3) . There was a group × time interaction for freezing and salivation (F[4, 30] ≥4.05, p≤ 0.01) and a main effect of group for body weight, ptosis, and leaning (F[2,30]≥5.11, p≤0.020). Post hoc analyses indicated that leaning and salivation were significantly different in rats that received clonidine with naloxone before conditioning trials, as compared to rats that received naloxone alone before conditioning or rats in which naloxone was not paired with the CS. Body weight, ptosis, and freezing were not different in rats that received clonidine with naloxone before conditioning trials (Group 7), as compared to rats that received naloxone alone before conditioning (Group 5).
Experiment 5: Determine whether morphine or clonidine modifies the expression of conditioned withdrawal. No significant differences in naloxone-precipitated withdrawal were detected between Groups 5 and 8 (t[10]≤1.23, NS), and only ptosis was significantly different between Groups 5 and 9 (t[10]=2.65, p=0.025; other four signs: t[10]≤2.15, NS; points above PW, Fig. 4) . Morphine prevented conditioned withdrawal-induced weight loss, ptosis, freezing, and salivation (t[10]=2.66, p<0.05; solid triangles, left panels, Fig. 4 ). Leaning was not significantly different in rats that received morphine before the test for conditioned withdrawal and those that did not (t[10]=2.50,NS). When tested 1 week later in the absence of morphine, conditioned withdrawal signs were not different between rats that received morphine on test day 8 and those that did not (t[10]≤ 1.85, NS). In contrast to morphine, clonidine attenuated fewer conditioned withdrawal signs. Clonidine prevented the emergence of conditioned-withdrawal induced ptosis and salivation (t[10]≥2.64, p<0.05) and did not prevent weight loss, leaning, or freezing (t[10]≤2.33, NS). Conditioned withdrawal signs observed 1 week later (test day 15) were not different between rats that received clonidine on test day 8 and those that did not (t[10]≤2.03, NS).
Discussion
The abuse of opioids remains a serious concern and admissions to substance abuse treatment programs is increasing (Treatment Episode Data Set 2006; http://www. figure (circles and squares) . Ordinates: top row, change in body weight (g) that occurred during the 30 min session; bottom four rows, frequency of directly observable signs. *P<0.05 for naloxone only versus naloxone plus clonidine (Groups 5 versus 7). See Fig. 1 for other details oas.samhsa.gov), although relapse rates remain high (Gossop et al. 2002) . Avoidance of withdrawal when opioid treatment is discontinued might contribute to continued drug use; however, relapse can occur long after the last drug use when withdrawal is not apparent. Stimuli previously associated with drug use (Siegal 1977; Weinstein et al. 1997) or drug withdrawal (Wikler 1948; O'Brien et al. 1976 ) might contribute to relapse months after discontinuation of drug use (Sell et al. 1995; Weinstein et al. 1997) , suggesting that conditioned effects of both abused drugs and their absence might need to be managed therapeutically. These studies compared antagonistprecipitated and conditioned opioid withdrawal in rats and examined whether conditioned withdrawal can be modified pharmacologically.
Conditions were identified that reliably produce conditioned withdrawal, including the number of pairings between the CS and withdrawal. In a conditioned place aversion procedure, conditioned withdrawal is evident in rats after a single pairing, although conditioned withdrawal is greater after two pairings (Azar et al. 2003 ). In the current study, a single pairing of the CS with naloxoneprecipitated withdrawal also was sufficient to produce conditioned withdrawal-induced weight loss. In morphinetreated subjects, the potency of naloxone to precipitate withdrawal increases with repeated naloxone administration . Consequently, more conditioning trials might enhance sensitivity to naloxone, thereby increasing conditioned withdrawal; this possibility was supported by the increased frequency of observable signs with three conditioning trials.
The duration of morphine treatment might also impact precipitated and conditioned withdrawal. In the current study, a dose of 3.2 mg/kg of naloxone precipitated withdrawal following repeated intermittent or chronic morphine treatment, although some naloxone-precipitated withdrawal signs were greater in rats that were treated daily with morphine at the time of conditioning, as compared to rats that received morphine less frequently. Weight loss was greater after the second and third conditioning trials in rats receiving morphine chronically, as compared to rats receiving morphine less frequently. Although the frequency of ptosis and leaning was not different in rats receiving morphine across different dosing conditions, the occurrence of freezing and salivation was higher in rats receiving morphine chronically. Differences in precipitated withdrawal among groups did not predict differences in conditioned withdrawal. Thus, whether or not rats were physically dependent during or prior to conditioning did not significantly impact the magnitude of conditioned withdrawal. Because a large dose of naloxone was used to precipitate withdrawal, it is possible that a ceiling effect limited the magnitude of precipitated and conditioned withdrawal. Thus, current or past dependence on morphine might impact the potency, if not the maximum effectiveness, of naloxone in precipitating withdrawal and in producing conditioned withdrawal. In rats, conditioned opioid withdrawal can last for many weeks (e.g., place aversion). Moreover, conditioned withdrawal Fig. 4 Effects of morphine and clonidine on established conditioned withdrawal. Ordinates: top row, change in body weight (g) that occurred during the 30 min session; bottom four rows, frequency of directly observable signs. *P<0.05 for saline versus morphine and saline versus clonidine (Groups 5 versus 8 and 5 versus 9). Filled symbols denote session preceded by a single injection of morphine (filled, inverted triangles) or clonidine (filled diamonds). See Fig. 1 for other details decreases when rats are repeatedly exposed to the CS in the absence of the unconditioned stimulus (Stinus et al. 2000) . In the current study, repeated testing of the same rats might have facilitated extinction of conditioned withdrawal; rapid extinction among all rats precluded examination of whether withdrawal signs were differentially resistant to extinction among treatments.
Changes in withdrawal were also examined in nondependent rats with a history of physical dependence. For weight loss, freezing, and salivation, the magnitude of precipitated withdrawal was greater in rats that were previously physically dependent, as compared to rats that were never dependent. Despite differences in precipitated withdrawal, the magnitude of conditioned withdrawal was similar between groups, further supporting the view that the magnitude of conditioned withdrawal is not entirely predicted by the magnitude of precipitated withdrawal during conditioning.
To determine whether the development of conditioned withdrawal is modified pharmacologically, clonidine was administered with naloxone before conditioning sessions. Clonidine attenuated naloxone-precipitated withdrawal with ptosis and salivation being most affected; clonidine prevented the emergence of these signs, which likely contributed to the significantly reduced frequency of conditioned ptosis and salivation. Clonidine attenuated naloxone-induced body weight decreases during the first two (data not shown) but not the third and final conditioning trial, perhaps because dependence might have increased over repeated injections of morphine (e.g., a larger dose of clonidine might be required with greater dependence). Conditioned withdrawal-induced weight loss was similar between rats that received clonidine with naloxone and those that received only naloxone, possibly related to the reduced effectiveness of clonidine in preventing naloxone-induced weight loss on the last conditioning trial. In another study, clonidine prevented precipitated withdrawal and, subsequently, conditioned withdrawal (Schulteis et al. 1998) . Together, these results suggest that clonidine disrupts some aspects of conditioned withdrawal by blocking precipitated withdrawal signs.
Precipitated or discontinuation-induced withdrawal is attenuated by the treatment drug or by pharmacologically equivalent drugs; it is less clear which drugs alter conditioned withdrawal. In morphine-dependent monkeys, a light, previously paired with an injection of the opioid antagonist nalorphine, increased morphine self-administration (Goldberg et al. 1969) , suggesting that conditioned withdrawal contributes to drug-taking and might promote relapse. The current study extends those findings and shows that conditioned withdrawal is prevented by morphine (and reduced by clonidine). Although the effects of morphine on conditioned withdrawal-induced weight loss might be due to its constipating effects (Galligan and Burks 1983) , the prevention of observable withdrawal signs indicates that morphine attenuates conditioned withdrawal. Clonidine prevented the expression of some conditioned withdrawal signs, consistent with a study in which opioid-dependent patients received either placebo or a different α2 adrenergic agonist, lofexidine. After discontinuation of opioid treatment, patients receiving lofexidine had reduced heart rates, attenuated drug cue-and stress-induced "craving" of opioids, higher abstinence rates, and improved relapse outcome (Sinha et al. 2007 ). In the current study, clonidine did not alter conditioned withdrawal-induced weight loss, leaning, or freezing. Larger doses of clonidine might be needed to attenuate all conditioned withdrawal signs, although the dose of clonidine in this study (0.1 mg/kg) blocks withdrawalinduced diarrhea in morphine-dependent rats (Sparber and Meyer 1978; DiStefano and Brown 1985) and decreases locomotor activity and schedule-controlled responding in untreated rats (Schulteis et al. 1998) . Alternatively, clonidine might selectively, or most effectively, prevent a subset of conditioned withdrawal effects, particularly those measured by suppression of operant responding or place aversion (Schulteis et al. 1998) . Nevertheless, conditioned withdrawal can be reduced pharmacologically, perhaps providing a strategy for preventing relapse.
In summary, conditioned withdrawal in rats increases as the number of conditioning trials or the duration of morphine treatment increases, and while a history of physical dependence enhances precipitated withdrawal for a fixed dose of antagonist, it does not further increase conditioned withdrawal. The development and expression of conditioned withdrawal can be modified pharmacologically; from a clinical perspective, focusing treatment on preventing the expression of conditioned withdrawal, rather than its development, might be more practical. Future studies might examine the therapeutic potential of other classes of drugs specifically for preventing the expression of conditioned withdrawal, perhaps by accelerating extinction of this learned response.
